Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells

G. Y. Jang, J. H. Jeon, S. Y. Cho, D. M. Shin, C. W. Kim, E. M. Jeong, H. C. Bae, Tae Woo Kim, S. H. Lee, Y. Choi, D. S. Lee, S. C. Park, I. G. Kim

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The expression of hypoxia-inducible factor-1 (HIF-1) correlates with poor clinical outcomes and confers resistance to the apoptosis of the tumor cells that are exposed to hypoxia. Presently, the mechanism underlying this phenomenon is poorly understood. In this study we provide evidence that transglutaminase 2 (TG2), an enzyme that catalyses protein crosslinking reactions, is a transcriptional target of HIF-1 to enhance the survival of hypoxic cells. We found that hypoxia induces TG2 expression through an HIF-1 dependent pathway and concurrently activates intracellular TG2. The hypoxic cells overexpressing TG2 showed resistance to apoptosis. Conversely, the hypoxic cells treated with either TG2 inhibitor or small interfering RNA (siRNA) became sensitive to apoptosis. Activation of TG2 in response to hypoxic stress inhibited caspase-3 activity by forming crosslinked multimer, resulting in insoluble aggregates. TG2 also activates nuclear factor (NF)-κB pathway after hypoxic stress, and thereby induces the expression of cellular inhibitor of apoptosis 2. The anti-apoptotic role of TG2 was further confirmed in vivo using xenografts in athymic mice. Our results indicate that TG2 is an anti-apoptotic mediator of HIF-1 through modulating both apoptosis and survival pathways and may confer a selective growth advantage to tumor cells. These findings suggest that the inhibition of TG2 may offer a novel strategy for anticancer therapy.

Original languageEnglish
Pages (from-to)356-367
Number of pages12
JournalOncogene
Volume29
Issue number3
DOIs
Publication statusPublished - 2010 Jan

Fingerprint

Caspase 3
Apoptosis
Hypoxia-Inducible Factor 1
Neoplasms
transglutaminase 2
Heterografts
Nude Mice
Small Interfering RNA
Cell Survival
Enzymes
Growth

Keywords

  • Apoptosis
  • Caspase 3
  • Hypoxia-inducible factor-1
  • NF-κB
  • Transglutaminase 2

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Jang, G. Y., Jeon, J. H., Cho, S. Y., Shin, D. M., Kim, C. W., Jeong, E. M., ... Kim, I. G. (2010). Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells. Oncogene, 29(3), 356-367. https://doi.org/10.1038/onc.2009.342

Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells. / Jang, G. Y.; Jeon, J. H.; Cho, S. Y.; Shin, D. M.; Kim, C. W.; Jeong, E. M.; Bae, H. C.; Kim, Tae Woo; Lee, S. H.; Choi, Y.; Lee, D. S.; Park, S. C.; Kim, I. G.

In: Oncogene, Vol. 29, No. 3, 01.2010, p. 356-367.

Research output: Contribution to journalArticle

Jang, GY, Jeon, JH, Cho, SY, Shin, DM, Kim, CW, Jeong, EM, Bae, HC, Kim, TW, Lee, SH, Choi, Y, Lee, DS, Park, SC & Kim, IG 2010, 'Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells', Oncogene, vol. 29, no. 3, pp. 356-367. https://doi.org/10.1038/onc.2009.342
Jang, G. Y. ; Jeon, J. H. ; Cho, S. Y. ; Shin, D. M. ; Kim, C. W. ; Jeong, E. M. ; Bae, H. C. ; Kim, Tae Woo ; Lee, S. H. ; Choi, Y. ; Lee, D. S. ; Park, S. C. ; Kim, I. G. / Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells. In: Oncogene. 2010 ; Vol. 29, No. 3. pp. 356-367.
@article{20ff91bfb96e49749ac2af0151b216e1,
title = "Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells",
abstract = "The expression of hypoxia-inducible factor-1 (HIF-1) correlates with poor clinical outcomes and confers resistance to the apoptosis of the tumor cells that are exposed to hypoxia. Presently, the mechanism underlying this phenomenon is poorly understood. In this study we provide evidence that transglutaminase 2 (TG2), an enzyme that catalyses protein crosslinking reactions, is a transcriptional target of HIF-1 to enhance the survival of hypoxic cells. We found that hypoxia induces TG2 expression through an HIF-1 dependent pathway and concurrently activates intracellular TG2. The hypoxic cells overexpressing TG2 showed resistance to apoptosis. Conversely, the hypoxic cells treated with either TG2 inhibitor or small interfering RNA (siRNA) became sensitive to apoptosis. Activation of TG2 in response to hypoxic stress inhibited caspase-3 activity by forming crosslinked multimer, resulting in insoluble aggregates. TG2 also activates nuclear factor (NF)-κB pathway after hypoxic stress, and thereby induces the expression of cellular inhibitor of apoptosis 2. The anti-apoptotic role of TG2 was further confirmed in vivo using xenografts in athymic mice. Our results indicate that TG2 is an anti-apoptotic mediator of HIF-1 through modulating both apoptosis and survival pathways and may confer a selective growth advantage to tumor cells. These findings suggest that the inhibition of TG2 may offer a novel strategy for anticancer therapy.",
keywords = "Apoptosis, Caspase 3, Hypoxia-inducible factor-1, NF-κB, Transglutaminase 2",
author = "Jang, {G. Y.} and Jeon, {J. H.} and Cho, {S. Y.} and Shin, {D. M.} and Kim, {C. W.} and Jeong, {E. M.} and Bae, {H. C.} and Kim, {Tae Woo} and Lee, {S. H.} and Y. Choi and Lee, {D. S.} and Park, {S. C.} and Kim, {I. G.}",
year = "2010",
month = "1",
doi = "10.1038/onc.2009.342",
language = "English",
volume = "29",
pages = "356--367",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells

AU - Jang, G. Y.

AU - Jeon, J. H.

AU - Cho, S. Y.

AU - Shin, D. M.

AU - Kim, C. W.

AU - Jeong, E. M.

AU - Bae, H. C.

AU - Kim, Tae Woo

AU - Lee, S. H.

AU - Choi, Y.

AU - Lee, D. S.

AU - Park, S. C.

AU - Kim, I. G.

PY - 2010/1

Y1 - 2010/1

N2 - The expression of hypoxia-inducible factor-1 (HIF-1) correlates with poor clinical outcomes and confers resistance to the apoptosis of the tumor cells that are exposed to hypoxia. Presently, the mechanism underlying this phenomenon is poorly understood. In this study we provide evidence that transglutaminase 2 (TG2), an enzyme that catalyses protein crosslinking reactions, is a transcriptional target of HIF-1 to enhance the survival of hypoxic cells. We found that hypoxia induces TG2 expression through an HIF-1 dependent pathway and concurrently activates intracellular TG2. The hypoxic cells overexpressing TG2 showed resistance to apoptosis. Conversely, the hypoxic cells treated with either TG2 inhibitor or small interfering RNA (siRNA) became sensitive to apoptosis. Activation of TG2 in response to hypoxic stress inhibited caspase-3 activity by forming crosslinked multimer, resulting in insoluble aggregates. TG2 also activates nuclear factor (NF)-κB pathway after hypoxic stress, and thereby induces the expression of cellular inhibitor of apoptosis 2. The anti-apoptotic role of TG2 was further confirmed in vivo using xenografts in athymic mice. Our results indicate that TG2 is an anti-apoptotic mediator of HIF-1 through modulating both apoptosis and survival pathways and may confer a selective growth advantage to tumor cells. These findings suggest that the inhibition of TG2 may offer a novel strategy for anticancer therapy.

AB - The expression of hypoxia-inducible factor-1 (HIF-1) correlates with poor clinical outcomes and confers resistance to the apoptosis of the tumor cells that are exposed to hypoxia. Presently, the mechanism underlying this phenomenon is poorly understood. In this study we provide evidence that transglutaminase 2 (TG2), an enzyme that catalyses protein crosslinking reactions, is a transcriptional target of HIF-1 to enhance the survival of hypoxic cells. We found that hypoxia induces TG2 expression through an HIF-1 dependent pathway and concurrently activates intracellular TG2. The hypoxic cells overexpressing TG2 showed resistance to apoptosis. Conversely, the hypoxic cells treated with either TG2 inhibitor or small interfering RNA (siRNA) became sensitive to apoptosis. Activation of TG2 in response to hypoxic stress inhibited caspase-3 activity by forming crosslinked multimer, resulting in insoluble aggregates. TG2 also activates nuclear factor (NF)-κB pathway after hypoxic stress, and thereby induces the expression of cellular inhibitor of apoptosis 2. The anti-apoptotic role of TG2 was further confirmed in vivo using xenografts in athymic mice. Our results indicate that TG2 is an anti-apoptotic mediator of HIF-1 through modulating both apoptosis and survival pathways and may confer a selective growth advantage to tumor cells. These findings suggest that the inhibition of TG2 may offer a novel strategy for anticancer therapy.

KW - Apoptosis

KW - Caspase 3

KW - Hypoxia-inducible factor-1

KW - NF-κB

KW - Transglutaminase 2

UR - http://www.scopus.com/inward/record.url?scp=75149182667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149182667&partnerID=8YFLogxK

U2 - 10.1038/onc.2009.342

DO - 10.1038/onc.2009.342

M3 - Article

C2 - 19838207

AN - SCOPUS:75149182667

VL - 29

SP - 356

EP - 367

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 3

ER -